. 2014 Mar 19;2014:758212. doi: 10.1155/2014/758212

Table 2.

Incidence of serious adverse events, discontinuations due to adverse events, and treatment-emergent adverse events during the double-blind treatment phase.

Safety measure	Double-blind treatment phase			P value^a
Safety measure	Pomaglumetad methionil N = 511	Aripiprazole N = 161	Total N = 672	P value^a
SAEs	42 (8.2)	5 (3.1)	47 (7.0)	0.032*
Discontinuations due to AEs	83 (16.2)	14 (8.7)	97 (14.4)	0.020*
TEAEs	370 (72.4)	109 (67.7)	479 (71.3)	0.272

*P < 0.05.

^a P values are from Fisher's exact test.

AE: adverse event; N: total number of patients in each treatment group; SAE: serious adverse event; TEAE: treatment-emergent adverse event.